Woodford Investment Management
Investor profile
Investment firm
Also recorded as: Woodford Investment Management Ltd
Deals
26
distinct rounds
Companies
21
backed
Active span
2014–2018
5 yrs
Total round €
€1.1B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- IP Group PLC3
- Lansdowne Partners3
- DN Capital2
- Imperial Innovations Limited2
- Invesco Perpetual2
- Oxford Sciences Innovation2
- Accelerated Digital Ventures1
- Artemis1
- Augmentum1
- BAE Systems1
- Baillie Gifford Asset Management1
- BBVA1
- Boeing HorizonX Ventures1
- British Business Bank1
- Cambridge Enterprise1
- Cambridge Innovation Capital1
- Cornes1
- Dolby Family Ventures1
- GV (Google Ventures)1
- Infracapital1
- Invesco1
- Kernel Capital Partners1
- Lightstone Ventures1
- Octopus Ventures1
- Rolls-Royce1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Gigaclear | UK | 2 | €166M |
| Oxford Nanopore Technologies | UK | 1 | €103M |
| BenevolentAI | UK | 1 | €99M |
| Atom Bank | UK | 1 | €98M |
| CeQur | Switzerland | 1 | €91M |
| Carrick Therapeutics | Ireland | 1 | €86M |
| Benevolent | UK | 1 | €80M |
| Cell Medica | UK | 1 | €60M |
| Ultrahaptics | UK | 3 | €55M |
| Kymab | UK | 1 | €45M |
| Nexeon | UK | 1 | €42M |
| Reaction Engines | UK | 1 | €30M |
| Genomics | UK | 1 | €28M |
| Drayson Technologies | UK | 2 | €28M |
| Eve Mattress | UK | 1 | €17M |
| SEEDrs | UK | 2 | €16M |
| RateSetter | UK | 1 | €15M |
| Oxsybio | UK | 1 | €11M |
| PurpleBricks | UK | 1 | €9.6M |
| Metaboards | UK | 1 | €4.3M |
| B-Secur | Ireland | 1 | €3.9M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Gigaclear | Other | €124M | 2017-05 |
| Oxford Nanopore Technologies | Growth/Late | €103M | 2016-03 |
| BenevolentAI | Other | €99M | 2018-01 |
| Atom Bank | Growth/Late | €98M | 2015-10 |
| CeQur | Series C | €91M | 2015-08 |
| Carrick Therapeutics | Series A | €86M | 2016-09 |
| Benevolent | Growth/Late | €80M | 2015-07 |
| Cell Medica | Series B | €60M | 2014-10 |
| Kymab | Series B | €45M | 2015-04 |
| Nexeon | Growth/Late | €42M | 2016-04 |